Assessment of Dyslipidemia

Assessment of Dyslipidemia

• Two fasting lipoprotein measurements should be taken to classify the patient’s CV risk, prior to initiating drug treatment or intensive lifestyle treatment. 

 If the total cholesterol level varies more than 30 - 40 mg/dL (> 16%)

in the two samples a third sample should be taken and the average of the three samples should be used as the baseline measure.

v Abnormal lipid test results should always be confirmed with a new specimen within 1–8 weeks of the initial test, before beginning or changing therapy.

v The sample should not be performed during stress or acute illness, such as recent MI, stroke, pregnancy, trauma,

weight loss or following the use of certain drugs, and should not be performed on hospitalized patients until 2-3 months after illness.

Secondary Dyslipidemia

It must be ruled out through medical, dietary, family history and physical evaluation to determine additional risk factors and any genetic factors.

Laboratory testing including FBS, LFT, RFT, TSH (other endocrine function test if indicated), erythrocyte volume and urinalysis must be done in addition to clinical evaluation.

Decreased HDL level	Increased triglyceride level	Increased LDL level
1- Diabetes mellitus 2- Cigarette smoking 3- Abdominal Obesity 4- Hypertriglyceridemia 5- Uremia 6- Menopause 7- Puberty (in males) 8- Anabolic steroids 9- Beta-adrenergic blockers 10- Progestins	1- Diabetes mellitus 2- Hypothyroidism 3- Abdominal Obesity 4- Alcoholism 5- Renal insufficiency 6- Beta-adrenergic blockers 7- Bile acid binding resins 8- Estrogens	1- Diabetes mellitus 2- Hypothyroidism 3- Nephrotic syndrome 4- Obstructive liver disease 5- Anabolic steroids 6- Progestins 7- Beta-adrenergic blockers 8- Thiazides

v Genetics disorders:.

If TC ≥ 300mg/dL (7.8 mmol/L) or if there is a family history of  premature coronary heart disease genetic disorders should be considered